CDTX vs. ENTX, GNTA, LENZ, ALGS, AVRO, IKNA, TSBX, ELUT, ATRA, and TIL
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Entera Bio (ENTX), Genenta Science (GNTA), LENZ Therapeutics (LENZ), Aligos Therapeutics (ALGS), AVROBIO (AVRO), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.
Cidara Therapeutics (NASDAQ:CDTX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.
Entera Bio has lower revenue, but higher earnings than Cidara Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Entera Bio has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -33.19%. Entera Bio's return on equity of -101.78% beat Cidara Therapeutics' return on equity.
Cidara Therapeutics currently has a consensus target price of $71.25, indicating a potential upside of 458.82%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 296.83%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cidara Therapeutics is more favorable than Entera Bio.
Cidara Therapeutics received 265 more outperform votes than Entera Bio when rated by MarketBeat users. Likewise, 70.19% of users gave Cidara Therapeutics an outperform vote while only 66.80% of users gave Entera Bio an outperform vote.
35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 7.4% of Cidara Therapeutics shares are held by insiders. Comparatively, 8.9% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Cidara Therapeutics had 1 more articles in the media than Entera Bio. MarketBeat recorded 2 mentions for Cidara Therapeutics and 1 mentions for Entera Bio. Cidara Therapeutics' average media sentiment score of 1.87 beat Entera Bio's score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the media.
Cidara Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
Summary
Cidara Therapeutics beats Entera Bio on 12 of the 19 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
